Best Menopause Telehealth Providers in 2026: Verified Costs & States

Editorial research — not medical advice. Consult a licensed clinician before starting, stopping, or changing hormone therapy. Prices verified May 26, 2026 at each provider’s public pricing page. See our affiliate disclosure and methodology.

The best menopause telehealth provider in 2026 depends on three things: your insurance, whether you want FDA-approved or compounded hormones, and whether you want a live video visit or messaging-only care. For most women with PPO insurance, Midi Health is the strongest place to start. For cash-pay women who want FDA-approved hormones at the lowest published monthly price, Alloy lists its estradiol patch at $74.99/month with progesterone available alongside it. For women who specifically want compounded bioidentical hormone therapy and a fast, no-labs start, Winona is the most established platform in that category — with the clear caveat that compounded medications are not FDA-approved finished products.

Below is the side-by-side comparison, the real first-90-day cost math, the FDA-approved vs compounded distinction in plain English, and a 60-second quiz that matches you to the right provider for your situation. We verified every price and policy directly at each provider’s website in May 2026.

Quick Answer: Which Menopause Telehealth Provider Should You Start With?

The right menopause telehealth provider depends on your situation. Midi Health fits most PPO-insured women across all 50 states (but does not cover Medicare or Medicaid). Alloy publishes the lowest monthly price for FDA-approved hormones if you’re paying cash. Winona is the option for compounded bioidentical hormone therapy with no labs and a fast start — though compounded medications are not FDA-approved finished products. Evernow has the lowest annual-equivalent membership price. Gennev and Stella accept insurance for the video visit. Wisp is the fastest path for vaginal or local symptoms.

What We Actually Verified for This Guide

The 9 Best Menopause Telehealth Providers Compared (May 2026)

Below are the nine major menopause telehealth providers in the US, compared on the factors that actually decide the right choice: starting cost, insurance, FDA-approved vs compounded medication, live video vs messaging-only, lab requirements, clinician credentials, and state availability. All data was verified directly at each provider’s website in May 2026.

A few things this table will tell you that most “top 15 menopause clinics” lists usually won’t. First, the cheapest sticker price almost never includes medication. Evernow’s $35/month is the annual-equivalent membership only — your patches or pills are extra. Second, “accepts insurance” usually means one of two things — either the platform bills your medical plan for the visit, or prescriptions go to a local pharmacy where your drug insurance applies. Rarely both, unless you’re at Midi with PPO. Third, compounded is not FDA-approved. We explain this in plain English below.

How Much Does Menopause Telehealth Actually Cost in 2026?

Menopause telehealth costs roughly $35 to $250+ per month depending on the provider, the medication, and whether you use insurance. The number that matters most is your first 90 days: consultation fee + medication for three months + any required labs + shipping. For most women, that lands between $200 and $800 out of pocket if you’re paying cash, and as low as a copay-only $50–$150 if you have a PPO plan that covers the visit. These are estimates from provider-published pricing — your actual cost depends on your medication, dosage, and pharmacy.

The “starting price” in big letters on a provider’s homepage is rarely the all-in cost. Three things hide inside it.

One: membership and medication are usually billed separately.Evernow’s $35/month annual-equivalent is just the access fee — you still pay for your patch or pills, either through insurance at your pharmacy or through Evernow’s delivery pharmacy. Pandia Health is the same structure. Midi Health bills a visit fee or copay, then medication runs through your insurance or pharmacy separately.

Two: quarterly or annual billing changes the real number.Alloy bills its patch subscription as a 3-month supply per quarter. Hers’ $79/month for oral estradiol requires a 12-month plan commitment — the month-to-month price is materially higher. Pandia’s annual-equivalent rate of $34.99/month requires a 12-month plan, and cancellation requires notice before the next billing period with possible early-cancellation fees. If you might cancel after one or two months, those plans cost more than the advertised rate.

Three: insurance rarely covers what people assume. Insurance can dramatically lower the medication cost when you fill the prescription at a local pharmacy (where allowed). It almost never covers the telehealth visit fee itself at cash-pay platforms like Alloy, Winona, Hers, or Wisp. For insurance to cover the visit, you need an in-network platform — typically Midi, Gennev, Stella, or a select Evernow insurance-eligible video visit.

The First-90-Day Cost Formula

This is the math worth doing before you swipe your card:

Here’s an estimated 90-day picture at the top providers, based on provider-published pricing as of May 2026. These are estimates, not guarantees.

The lowest 90-day cash totals for a woman who wants FDA-approved hormones are typically Wisp + insurance at the pharmacy, Pandia on its annual-equivalent tier, or Evernow on its 3-month plan, followed by Alloy if you want predictable bundled pricing. With a PPO plan, Midi or Stella can drop the visit cost to a copay-only situation.

Best Menopause Telehealth That Takes Insurance

Three menopause telehealth providers consistently bill insurance for the telehealth visit itself in 2026: Midi Health (most PPOs, not Medicare or Medicaid), Gennev (many major plans in all 50 states), and Stella (insurance-first model with HSA/FSA and superbill options). Most other major platforms — Alloy, Winona, Hers, Evernow, Pandia, Wisp — are cash-pay for the visit itself. Several let you fill prescriptions at your local pharmacy where your drug insurance can apply. HSA and FSA cards are accepted at nearly every cash-pay platform.

There’s a difference between “insurance pays for my visit” and “insurance pays for my medication.” Most readers conflate the two and end up surprised.

Visit insurance. Only a few platforms bill your medical plan for the consultation. Midi is the broadest — most PPO plans (but not standard Medicare, any Medicare Advantage or other Medicare-related plan, Medicaid, or Medi-Cal). Gennev accepts many major plans. Stella accepts insurance plus offers superbills. Evernow has some insurance-eligible video visits available in select states without a membership commitment.

Medication insurance.Many FDA-approved estradiol or progesterone prescriptions can be filled at your local pharmacy through your existing drug coverage. Whether your specific provider can route the prescription to a local pharmacy depends on their fulfillment model — some platforms use their own delivery pharmacy and don’t route to local pharmacies for every product.

If you have a PPO plan, the typical math is: Midi + Rx through your local pharmacy with insurance = lowest total cost for most insured women in 2026.

Can the Prescription Go to My Local Pharmacy, or Does the Provider Ship It?

Some providers ship medication from their own pharmacy; others route prescriptions to your local pharmacy where your drug insurance can apply. Midi, Gennev, Stella, Pandia, Wisp, and Evernow can route prescriptions to your local pharmacy. Alloy, Winona, and Hers fulfill primarily through their own platform/delivery pharmacy. Always confirm during intake that your exact medication can be sent to your preferred pharmacy.

Reason one: your drug insurance only kicks in at a contracted pharmacy.If your platform fulfills only through its own delivery pharmacy and your drug plan doesn’t contract with it, you’ll pay cash for the medication regardless of what insurance you have. Local-pharmacy routing through CVS, Walgreens, Costco, or your independent pharmacy lets you use your existing drug coverage.

Reason two: supply matters.Reuters reported in April 2026 that estradiol patch demand had risen sharply. Platforms with the most flexibility on patch supply tend to be the ones that can route to local pharmacies. Hims & Hers stated in that reporting that it had steady patch supply through its own pharmacy.

The practical takeaway: if you want maximum flexibility and the ability to use your drug insurance, lean toward platforms that route to local pharmacies — Midi, Gennev, Stella, Pandia, Wisp, and Evernow. If you prefer the simplicity of one all-in subscription delivered to your door, Alloy, Winona, and Hers are designed for that.

What If I Have Medicare, Medicaid, or Medi-Cal?

Medicare and Medicaid coverage at menopause telehealth platforms is limited and inconsistent — do not assume coverage. Midi Health states clearly that it is not covered by Medicare or any Medicare-related insurance plan; Medicare beneficiaries can use Midi as self-pay patients but cannot submit any claims for Midi visits, medications, or associated services. Midi also cannot treat Medicaid or Medi-Cal patients at all, even as self-pay. Other providers vary widely; verify directly with the platform before booking.

Medicare and Medicare Advantage. Midi Health is not covered by Medicare or any Medicare-related plan including Medicare Advantage. Medicare beneficiaries can pay self-pay at Midi but cannot submit claims for visits, medications, or associated services. Other platforms’ Medicare coverage should be verified directly during intake — the answer is usually no for telehealth visits, though Medicare may still cover the prescription medication at a participating pharmacy.

Medicaid and Medi-Cal. Midi cannot treat Medicaid or Medi-Cal patients at all, even as self-pay. Most cash-pay telehealth platforms similarly cannot bill state programs. If you have Medicaid or Medi-Cal, your best path is usually an in-person provider in your state’s Medicaid network.

HSA/FSA cards. Nearly every cash-pay menopause platform accepts HSA and FSA cards for the visit fee and often the membership. This can offset costs meaningfully even if your insurance doesn’t apply.

FDA-Approved vs. Compounded Menopause Hormones: What the Difference Actually Means

FDA-approved menopause hormone therapy includes medications like estradiol patches, oral micronized progesterone, and combination products that have been reviewed by the FDA for safety, efficacy, and consistent manufacturing as finished drug products. Compounded bioidentical hormone therapy is custom-prepared at a compounding pharmacy and is not FDA-approved as a finished drug product. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed (fda.gov). Among the providers above, Alloy, Midi, Hers, Evernow, Pandia, Gennev, Stella, and Wisp prescribe FDA-approved hormones. Winona’s primary medications are compounded.

What “FDA-approved” means

An FDA-approved menopause hormone is a finished medication that’s gone through FDA review for three things: it works for the symptoms it claims to treat, the benefits outweigh the risks for its approved use, and it’s manufactured consistently — every batch has the same potency, the same ingredients, the same delivery into your body, with FDA-reviewed labeling. Estradiol patches like Vivelle-Dot, Climara, and Dotti are FDA-approved. So are oral estradiol pills, micronized progesterone capsules like Prometrium, vaginal estrogen products like Estrace and Vagifem, and combination patches like Climara Pro.

What “compounded” means

A compounded medication is made-to-order at a compounding pharmacy from raw hormone ingredients. The finished compounded preparation is notFDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed (fda.gov). Compounding can be appropriate in specific clinical situations: documented allergy to an inactive ingredient in the FDA-approved option, a dose strength that’s not commercially available, or a delivery form a patient genuinely can’t tolerate any other way.

What ACOG and the Menopause Society say

ACOG’s 2023 clinical consensus is direct: “Compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist.” The Menopause Society’s position is consistent — when hormone therapy is appropriate, the default recommendation is an FDA-approved product, with compounded preparations reserved for specific clinical reasons.

Why this matters for picking a provider

If you want an FDA-approved-first path, Midi, Alloy, Hers, Gennev, Evernow, Stella, Pandia, and Wisp are the right starting points.

If you specifically want compounded BHT — because you’ve researched it, because you’ve already used compounded hormones and prefer them, or because an FDA-approved option doesn’t work for your situation — Winonais the most established platform in that category. Many women have had positive experiences with compounded HRT. We’re telling you what the FDA, ACOG, and the Menopause Society say, so you can make an informed choice.

Is Online Menopause Care Safe? (And What the FDA Changed in 2025–2026)

Online menopause care can be a legitimate, clinically appropriate path for many healthy symptomatic women within 10 years of menopause onset, when a licensed clinician screens for contraindications, individualizes the plan, and provides follow-up. In November 2025, the FDA initiated labeling changes for menopausal hormone therapy products. On February 12, 2026, the FDA approved labeling changes to the first six products, removing boxed-warning risk statements related to cardiovascular disease, breast cancer, and probable dementia. The endometrial cancer boxed warning was retained for systemic estrogen-alone products in patients with a uterus. Individual risk-benefit decisions still belong with a licensed clinician.

What the FDA did in November 2025 → February 2026

For two decades, every prescription estrogen product in the United States carried a boxed warning — the FDA’s strongest safety label — listing increased risks of breast cancer, heart attack, stroke, blood clots, and probable dementia. Those warnings were added after the 2002 Women’s Health Initiative study. In July 2025, an FDA expert panel reviewed the science. In November 2025, HHS and the FDA announced they would initiate removal of broad boxed-warning language from menopausal hormone therapy products. On February 12, 2026, FDA approved labeling changes for the first six products. The boxed warnings related to cardiovascular disease, breast cancer, and probable dementia were removed from those labels.

What did notchange: the endometrial cancer boxed warning was retained for systemic estrogen-alone products in patients with a uterus — the medical reason progesterone is paired with estrogen in women who haven’t had a hysterectomy.

Who hormone therapy is and isn’t for

Hormone therapy is appropriate for many healthy women in perimenopause and menopause. The contraindications haven’t changed:

• Active or recent breast cancer or other hormone-sensitive cancer
• Unexplained vaginal bleeding (needs evaluation before HRT)
• Recent blood clot, deep vein thrombosis, pulmonary embolism, or stroke
• Active or chronic liver disease
• Known clotting disorders
• Possible pregnancy

A licensed online menopause clinician will screen for all of these in your intake. If you have any of them, telehealth is not the right starting point — you need in-person care first.

What separates a legitimate online provider from a sketchy one

1. Licensed in your state. Confirm the clinician is licensed where you live.
2. Real intake and contraindication screening. A serious provider asks about your medical history, family history of cancer, clotting history, and current medications.
3. Credentialed clinicians. Look for Menopause Society Certified Practitioners (MSCP, formerly NCMP), board-certified OB-GYNs, or board-certified internal medicine/family medicine clinicians with menopause training.
4. Transparent pricing. No surprise charges. Cancellation terms are visible.
5. Real cancellation policy. You can stop the subscription from the patient portal.
6. In-person referral path. A legitimate platform tells you when in-person care is safer — and helps you find it.

What About Estradiol Patch Availability in 2026?

Estradiol patches have been the subject of supply pressure and patient frustration in 2026. In April 2026 Reuters reporting, Hims & Hers stated it had steady patch supply through its own pharmacy. If a patch is your preferred form, choose a provider that can prescribe multiple patch brands and either ship reliably from its own pharmacy or route the prescription to your local pharmacy.

Three questions to ask your prospective provider before signing up:

1. Do you prescribe more than one estradiol patch brand? A platform that can write Vivelle-Dot, Climara, Dotti, Lyllana, or a generic interchangeably is more resilient.
2. Can you send my prescription to my local pharmacy if your delivery pharmacy is out? This is the single most useful flexibility a platform can offer right now.
3. If patches aren’t available, can you switch me to gel, spray, or oral estradiol without another consultation fee? A good provider does this for free as part of the same care plan.

The platforms that can route prescriptions to local pharmacies (Midi, Gennev, Stella, Pandia, Wisp, Evernow) tend to have more flexibility if supply shifts. Platforms with their own delivery pharmacy (Alloy, Hers, Winona) trade some flexibility for subscription simplicity. Confirm patch options and supply pathways at intake.

Do You Need Blood Tests Before Starting Menopause HRT Online?

Not always. Many menopause-trained clinicians base treatment decisions on your symptoms, age, menstrual history, medical history, and risk factors rather than a single hormone level. The Menopause Society’s position is that hormone levels are not required to diagnose menopause in women over 45 with classic symptoms. Labs may still be ordered to rule out other conditions or because a clinician judges them clinically appropriate. Among the providers in our comparison, Winona, Hers, Alloy, Pandia, and Wisp do not require labs by default. Midi, Gennev, and Stella may order labs depending on the clinician’s judgment.

Labs become more useful in a few specific situations:

• You’re under 40 or in your early 40s. Premature ovarian insufficiency needs a different workup.
• Your symptoms don’t fit the menopausal pattern. Persistent fatigue, weight changes, hair changes can overlap with thyroid issues.
• Abnormal bleeding. Always needs evaluation before HRT.
• You have a complex cardiometabolic profile. A lipid panel can help inform the choice of estrogen form.

If you want a provider that emphasizes labs and monitoring as part of routine care, Midi or Gennev is a better starting point. If you want the fastest, simplest path to a first prescription with no labs, Winona, Hers, Alloy, or Wisp will get you there.

Which Menopause Telehealth Providers Are Available in Your State?

Six providers serve all 50 US states: Midi Health, Alloy, Gennev, Wisp, and Evernow (all 50 + DC). Pandia Health serves most US states. Winona currently operates in 40+ states. Hers is not available in all 50 states — verify eligibility at intake. Stella’s state availability varies and should be confirmed during signup. State coverage changes regularly as platforms expand — verify at the provider’s intake before paying.

As of May 26, 2026:

Telehealth licensing is a per-state thing. A platform can be “available in all 50 states” overall but still have longer waitlists in smaller states. If you live in a less-populated state and want to start this week, ask the platform’s support team how soon a clinician licensed in your state can see you.

The 9 Providers in Depth

We walk through each major provider — who it’s best for, what we verified, where it falls short, and who should pick a different option.

Honorable Mentions

Sesame.Marketplace model with same-day menopause consultations. Pricing varies by chosen clinician. Better as a “I need an appointment this week” option than as a long-term menopause-specialist relationship.

MyMenopauseRx. Insurance-accepting with NCMP-certified physicians in approximately 29 states. Good fit for insured women in covered states who want NCMP-credentialed care; less universal than Midi or Gennev because of narrower geography.

How We Picked These Providers

We evaluated each menopause telehealth provider on six weighted criteria: menopause-specific clinical fit, price clarity and first-90-day predictability, insurance usefulness, medication transparency (FDA-approved vs compounded), availability and pharmacy practicality, and cancellation friction. Each provider was rated only against the public, verifiable data we could access in May 2026. Rankings reflect editorial fit conclusions based on those verified facts. They are not medical advice and should not replace a licensed clinician’s judgment.

What did not influence the rankings

• Affiliate payout
• Provider brand popularity alone
• Marketing claims that we couldn’t verify against the provider’s own pricing or policy pages
• Testimonials as proof of medical effectiveness

What to Verify Before You Pay

Before you enter a card, confirm seven things at the provider’s website or by contacting support: your state is served by a licensed clinician, the visit cost is clear, the medication form and FDA-approval status is what you expected, whether labs are required, whether your insurance applies, the cancellation policy, and what happens after any introductory pricing ends.

The Real Downsides of Menopause Telehealth (Honest Version)

Online menopause care is not fake. The real downsides are different from the ones marketing copy talks about: hidden total cost, uneven clinical depth across platforms, real state limitations, insurance complexity, medication form mismatches when supply shifts, cancellation friction on multi-month plans, and the choice to start online when in-person evaluation would be safer.

Downside one: the advertised price is rarely the all-in price. Memberships ≠ medication. 12-month plans ≠ month-to-month. Always do the 90-day math.

Downside two: insurance is harder than the marketing suggests. “Accepts insurance” might mean “your medication can be billed through your drug plan at a pharmacy,” not “we bill your medical plan for the visit.” Read carefully.

Downside three: compounded BHT is sometimes marketed as if it’s interchangeable with FDA-approved. It isn’t. We’ve explained this in plain English above.

Downside four: some women need in-person care first. Unexplained bleeding, a new breast lump, severe pelvic pain, complex cardiometabolic history, possible pregnancy, or symptoms suggesting something other than menopause all need in-person evaluation before HRT. A good online platform tells you this. A bad one charges your card anyway.

Downside five: cancellation terms vary widely. Pandia’s plans, Hers’ 12-month rate, Alloy’s quarterly billing — each has specific terms that don’t matter until you try to leave. Read the policy.

These are real. They are also avoidable with the checklist above.

What Real Patients Say (Real Reviews, Real Limits)

We include real, attributable testimonials only. We don’t use testimonials to support medical effectiveness claims. The reviews below are about the patient experience — intake, billing transparency, clinician communication.

Verified Trustpilot reviews are available for Alloy (4.4/5 from 2,100+ reviews per Innerbody’s verification of Alloy’s Trustpilot page), Winona, Evernow, and others — check the providers’ Trustpilot pages directly before you sign up if seeing many voices matters to you.

Frequently Asked Questions

Sources

• U.S. Food and Drug Administration. “FDA Approves Labeling Changes to Menopausal Hormone Therapy Products.” fda.gov, February 12, 2026.
• U.S. Food and Drug Administration. “HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy.” fda.gov, November 10, 2025.
• U.S. Food and Drug Administration. “Compounding and the FDA: Questions and Answers.” fda.gov.
• American College of Obstetricians and Gynecologists. “Compounded Bioidentical Menopausal Hormone Therapy.” Clinical Consensus No. 6, November 2023.
• The Menopause Society. Hormone Therapy Position Statement, current edition.
• Provider sources: joinmidi.com/pricing-insurance, myalloy.com/solutions, bywinona.com, evernow.com/faq, forhers.com/menopause, gennev.com/menopause-relief, pandiahealth.com/menopause, hellowisp.com/products/menopause-consult, us.onstella.com. All verified May 2026.
• Reuters. “Hims & Hers expands into menopause care as estrogen patch demand rises.” April 22, 2026.
• Innerbody Research. Alloy Menopause Reviews (Trustpilot rating verification), 2025–2026.

Last verified: May 26, 2026. Next scheduled re-verification: August 2026.